Spectrum Pharmaceuticals, Inc. (SPPI) said it received notification that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application, or sNDA, for FUSILEV for Injection in combination with 5-FU containing regimens in advanced metastatic colorectal cancer. The user fee goal date for the sNDA is October 8, 2009.
FUSILEV is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.